株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

帯状疱疹(帯状ヘルペス):パイプライン製品の分析

Herpes Zoster (Shingles) - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 232833
出版日 ページ情報 英文 63 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.92円で換算しております。
Back to Top
帯状疱疹(帯状ヘルペス):パイプライン製品の分析 Herpes Zoster (Shingles) - Pipeline Review, H1 2017
出版日: 2017年04月28日 ページ情報: 英文 63 Pages
概要

帯状疱疹(帯状ヘルペス)は、強い痛みを伴う水疱形成性の皮膚発疹で、水痘・帯状疱疹ウイルスによって引き起こされます。その症状には、発熱、悪寒、頭痛、関節痛などがあります。発病要因は年齢、免疫機能の低下などであり、抗ヒスタミン剤や鎮痛剤を治療に利用します。

当レポートでは、帯状疱疹(帯状ヘルペス)治療薬の開発状況について調査しており、パイプライン製品の概要、治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

  • 調査範囲

帯状疱疹(帯状ヘルペス)の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

帯状疱疹(帯状ヘルペス):企業で開発中の治療薬

帯状疱疹(帯状ヘルペス):パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

帯状疱疹(帯状ヘルペス):企業で開発中の製品

帯状疱疹(帯状ヘルペス)の治療薬開発に従事している企業

  • Astellas Pharma Inc.
  • Beijing Minhai Biotechnology Co., Ltd
  • ContraVir Pharmaceuticals, Inc.
  • Epiphany Biosciences, Inc.
  • Foamix Pharmaceuticals Ltd.
  • GeneOne Life Science, Inc.
  • GlaxoSmithKline Plc
  • Merck & Co., Inc.
  • NAL Pharmaceuticals Ltd.
  • ReceptoPharm, Inc.
  • TSRL, Inc.

帯状疱疹(帯状ヘルペス):治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • acyclovir
  • amenamevir
  • FV-100
  • GLS-5100
  • GSK-1437173A
  • herpes zoster vaccine
  • NAL-3221
  • NAL-3223
  • RPI-78M
  • TSR-087
  • V-212
  • valomaciclovir stearate

帯状疱疹(帯状ヘルペス):最近のパイプライン動向

帯状疱疹(帯状ヘルペス):休止中のプロジェクト

帯状疱疹(帯状ヘルペス):開発が中止された製品

帯状疱疹(帯状ヘルペス):製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9200IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Zoster (Shingles) - Pipeline Review, H1 2017, provides an overview of the Herpes Zoster (Shingles) (Infectious Disease) pipeline landscape.

Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain and swollen glands. The predisposing factors include age and weakened immune system. Treatment includes antihistamines and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Herpes Zoster (Shingles) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Herpes Zoster (Shingles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 3, 1, 1, 6 and 1 respectively.

Herpes Zoster (Shingles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Herpes Zoster (Shingles) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Herpes Zoster (Shingles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Herpes Zoster (Shingles) - Overview
  • Herpes Zoster (Shingles) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Herpes Zoster (Shingles) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development
    • Astellas Pharma Inc
    • Beijing Minhai Biotechnology Co Ltd
    • ContraVir Pharmaceuticals Inc
    • Epiphany Biosciences Inc
    • Foamix Pharmaceuticals Ltd
    • GeneOne Life Science Inc
    • GlaxoSmithKline Plc
    • Merck & Co Inc
    • NAL Pharmaceuticals Ltd
    • NanoViricides Inc
    • SK Chemicals Co Ltd
    • TSRL Inc
    • XBiotech Inc
  • Herpes Zoster (Shingles) - Drug Profiles
    • acyclovir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • amenamevir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FV-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GLS-5100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-1437173A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • herpes zoster vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Shingles - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAL-3223 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NBP-608 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NN-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Shingles - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TSR-087 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • V-212 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • valomaciclovir stearate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Herpes Zoster (Shingles) - Dormant Projects
  • Herpes Zoster (Shingles) - Discontinued Products
  • Herpes Zoster (Shingles) - Product Development Milestones
    • Featured News & Press Releases
      • Apr 18, 2017: GSK announces regulatory submission in Japan of its candidate vaccine for prevention of shingles
      • Feb 24, 2017: In First Phase 3 Trial, Merck's Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects
      • Nov 25, 2016: GSK announces EU regulatory submission of candidate vaccine for prevention of shingles - Follows regulatory submissions in US and Canada
      • Oct 27, 2016: GSK presents new data for shingles candidate vaccine at IDWeek scientific conference
      • Oct 24, 2016: GSK announces US regulatory submission of candidate vaccine for prevention of shingles
      • Sep 14, 2016: GSKs candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM
      • Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles
      • Apr 20, 2016: N&N Pharmaceuticals Commences Clinical Trials on its Novel Antiviral Drug
      • Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study
      • Oct 27, 2015: GSK's candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over
      • Sep 08, 2015: Clinical trial for Cardiff's shingles treatment
      • Aug 03, 2015: ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain
      • Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial
      • Apr 28, 2015: GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of 97.2% which does not diminish in the age groups studied
      • Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Herpes Zoster (Shingles), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Herpes Zoster (Shingles) - Pipeline by Astellas Pharma Inc, H1 2017
  • Herpes Zoster (Shingles) - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017
  • Herpes Zoster (Shingles) - Pipeline by ContraVir Pharmaceuticals Inc, H1 2017
  • Herpes Zoster (Shingles) - Pipeline by Epiphany Biosciences Inc, H1 2017
  • Herpes Zoster (Shingles) - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
  • Herpes Zoster (Shingles) - Pipeline by GeneOne Life Science Inc, H1 2017
  • Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Herpes Zoster (Shingles) - Pipeline by Merck & Co Inc, H1 2017
  • Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd, H1 2017
  • Herpes Zoster (Shingles) - Pipeline by NanoViricides Inc, H1 2017
  • Herpes Zoster (Shingles) - Pipeline by SK Chemicals Co Ltd, H1 2017
  • Herpes Zoster (Shingles) - Pipeline by TSRL Inc, H1 2017
  • Herpes Zoster (Shingles) - Pipeline by XBiotech Inc, H1 2017
  • Herpes Zoster (Shingles) - Dormant Projects, H1 2017
  • Herpes Zoster (Shingles) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Herpes Zoster (Shingles), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top